Trimel Pharmaceuticals

Trimel Pharmaceuticals develops medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders.

Trimel Pharmaceuticals Corporation, a specialty pharmaceutical company, engages in developing medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders. Its product pipeline includes CompleoTRT, a bioadhesive intranasal gel formulation of testosterone, which has completed Phase III clinical study for treating male hypogonadism; Tefina, an intranasal low-dose gel formulation of testosterone, which is in Phase II clinical study for treating female sexual dysfunction; TBS-3, an intranasal gel formulation of dopamine that has completed preclinical study for the treatment of Parkinson’s disease; and TBS-7 for the prevention and treatment of asthma symptoms. Its products also include TBS-5, which is in formulation development stage for the long-term treatment of airway inflammation caused by asthma; and TBS-6, which is in early stage exploratory development stage for the treatment of allergic rhinitis. The company was founded in 2008 and is headquartered in Mississauga, Canada.